Drugs / NK042
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07546110 | May 2026 → Dec 2027 expected | multiple sclerosis | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06676631 | Feb 2025 → Dec 2026 expected | lupus nephritis, systemic lupus erythematosus | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06773091 | Feb 2025 → Dec 2026 expected | cancer | Shanghai NK Cell Technology Co., LTD | Recruiting | No outcome recorded |
| Phase 1 | NCT06415500 | May 2024 → Dec 2025 overdue | female reproductive organ cancer | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06415500 ↗ |
| Modality | Cell therapy | “allogeneic, off-the-shelf cellular therapy” NCT07546110 ↗ |
| Route | Other | “NK042 intraperitoneal infusion on Days 0,7 and 14.” NCT06415500 ↗ |